Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Carrefour becomes first European retailer to offer shopping on ChatGPT - 2Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- 3How grandchildren are stepping up to fill the caregiver gap
- 4'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 5Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- A hospital discharged a woman in labor. This lawmaker wants change.
- The Best 15 Applications for Efficiency and Association
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- The Manual for Decent European Urban communities in 2024
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- First SpaceX booster for upgraded Starship fails during test in Texas
- Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- My Excursion to Monetary Autonomy: Awesome ways to save cash
